Meadowhawk rolls out biomarker services

New CRO Meadowhawk Biolabs has rolled out bioanalytical services to support small molecule drug developers and firms seeking to use biomarkers in clinical development.

The firm – which has operations in the Boston and San Francisco – announced the launch of its liquid chromatography mass spectrometry (LC/MS) services last week, explaining the aim is to work help small molecule drug developers working with biomarkers.

Meadowhawk was established last year by a team of experienced executives from Agilux Laboratories, the bioanalytical services firm that was acquired US CRO Charles River Laboratories in 2016.

This experience is key according to CEO Jim Jersey, who said, “As a group of dedicated professionals, we apply scientific insights and advances from biology, industrial engineering, information technology and other fields to advance our clients’ drug discovery and development."

He added that, “Innovative process engineering enables us to deliver results with incomparable speed and reliability. And it empowers our employees to add value where it counts.”

Meadowhawk plans to work with a broad range of customers according to Jersey, who said, “We are dedicated to forming long term, mutually beneficial relationships with our customers and to efficiently and interactively fulfilling the needs of even the smallest start-up.”

The firm also outlined plans to expand its service offering beyond biomarket analysis. By the middle of the year the intention is to roll out In-vivo rodent pharmacokinetic services as well as non-GLP large molecule bioanalytical services.

And next year Meadowhawk will begin offering good laboratory practice (GLP) grade bioanalytical services and in-vivo pharmacology services for large molecule drug developers, with oncology being a major focus.

Image: Stock Photo Secrets